Skip to main content
An official website of the United States government
Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

indium In 111-XYIMSR-01

A radioconjugate consisting of XYIMSR-01, a bivalent low molecular weight ligand targeting two separate sites on carbonic anhydrase IX (CAIX), conjugated with the bifunctional, macrocyclic chelating agent tetra-azacyclododecanetetra-acetic acid (DOTA) and labeled with indium In 111 (111In), with potential imaging activity during single photon emission computed tomography (SPECT). Upon administration of indium In 111-XYIMSR-01, XYIMSR-01 targets and binds to CAIX-expressing tumor cells, followed by internalization and retention of the radioisotope. This allows for imaging of CAIX-expressing tumor cells upon SPECT. CAIX is overexpressed in various tumors and plays a key role in intra- and extracellular pH regulation, cancer cell progression, survival, migration and invasion.
Check for active clinical trials using this agentView this agent in the NCI Thesaurus
Synonym:[111In]XYIMSR-01
111In-XYIMSR-01
Search NCI's Drug Dictionary
Please enter up to 30 characters for your search